Meeting
2015 ASCO Annual Meeting
Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.
Authors
Zev A. Wainberg
UCLA Medical Center, Los Angeles, CA
Zev A. Wainberg , Geoffrey Shapiro , Giuseppe Curigliano , Stephen Leong , Rebecca Sophie Kristeleit , Maria Alsina Maqueda , Carolyn D. Britten , Michele Milella , Mark R. Middleton , Anthony J. Olszanski , Ulka N. Vaishampayan , Jose A. Lopez-Martin , Karen A. Gelmon , Nicoletta Brega , Kristen J. Pierce , Rachelle Perea , Brett Edward Houk , Nuzhat Pathan , Ashwin Gollerkeri , Albiruni R. A. Razak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Signal Transduction
Clinical Trial Registration Number
NCT01920061
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2590)
DOI
10.1200/jco.2015.33.15_suppl.2590
Abstract #
2590
Poster Bd #
306
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib.
First Author: Zev A. Wainberg
Poster
2015 Breast Cancer Symposium
Dual inhibition of DNA double strand break (DSB) repair and PI3K pathway with BEZ235 (BEZ) to sensitize refractory metastatic (met) triple negative breast cancer (TNBC) to nab paclitaxel/cisplatin (pac/cis) in a patient with an exceptional response (ExRx).
First Author: Joyce O'Shaughnessy
Poster
2015 ASCO Annual Meeting
A phase I study of temsirolimus plus erlotinib in patients with refractory solid tumors.
First Author: Andrea Wang-Gillam
Poster
2020 ASCO Virtual Scientific Program
Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.
First Author: Leora Horn